Endpoints were rate of rebleeding and mortality till day 30 after inclusion and to see for any adverse events. Results: The bleeding was stopped in all 15 patients (100%). Rebleeding till day 30 was observed in 4 (26%) patients (2 each in group A and B). Total 2 patients (13%) died (1 each in both groups) due to rebleeding. Transfusion needs were higher in group A (4.2±2.8 versus 2.3±2.1, p<.05). Serious adverse effects leading to treatment discontinuation were not seen in any patients in both groups. Conclusion: Prolonging terlipressin treatment did not confer any significant decrease of mortality or bleeding recurrence. However transfusion requirements were significantly decreased in patients receiving prolonged treatment. Serious adverse effects leading to treatment discontinuation are rare.